We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

24 hedge funds and large institutions have $39.5M invested in Arbutus Biopharma in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

341% more capital invested

Capital invested by funds: $8.95M → $39.5M (+$30.5M)

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

33% more funds holding

Funds holding: 18 → 24 (+6)

Holders
24
Holders Change
+6
Holders Change %
+33.33%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
6
Reduced
1
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$16.8M
2
SM
Sabby Management
Florida
+$4.32M
3
BBA
Baker Bros. Advisors
New York
+$4.16M
4
PC
PointState Capital
New York
+$2.9M
5
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
+$1.76M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$1.11M
2
KA
Kerrisdale Advisers
Florida
-$626K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$410K
4
LOM
Loeb Offshore Management
New York
-$70K
5
FANJ
Financial Architects (New Jersey)
New Jersey
-$63K
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
1
Franklin Resources
California
$16.1M +$16.8M +2,022,400 New
Bank of Montreal
2
Bank of Montreal
Ontario, Canada
$5.97M -$410K -49,270 -6%
SM
3
Sabby Management
Florida
$4.14M +$4.32M +519,200 New
BBA
4
Baker Bros. Advisors
New York
$3.98M +$4.16M +500,000 New
PC
5
PointState Capital
New York
$2.77M +$2.9M +348,000 New
AWMDMG
6
Austin W. Marxe & David M. Greenhouse
New York
$1.96M +$1.76M +211,292 +617%
B
7
Bailard
California
$923K +$965K +115,795 New
BIM
8
Bogle Investment Management
Massachusetts
$764K +$799K +95,897 New
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$579K +$606K +72,724 New
IGIM
10
I.G. Investment Management
Manitoba, Canada
$507K – – –
Deutsche Bank
11
Deutsche Bank
Germany
$412K +$49.1K +5,900 +13%
OAM
12
Orinda Asset Management
California
$241K +$152K +18,230 +152%
VKH
13
Virtu KCG Holdings
New York
$223K +$125K +14,968 +113%
ARTA
14
A.R.T. Advisors
New York
$213K +$224K +26,832 New
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$144K – – –
SKK
16
Shepherd Kaplan Krochuk
Massachusetts
$139K – – –
EA
17
Emerald Advisers
Pennsylvania
$121K +$127K +15,200 New
Goldman Sachs
18
Goldman Sachs
New York
$116K +$121K +14,557 New
SIM
19
Spark Investment Management
New York
$81K – – –
TRCT
20
Tower Research Capital (TRC)
New York
$31K +$21.9K +2,631 +205%
U
21
UBS
Switzerland
$16K +$6.19K +743 +62%
HCM
22
Highlander Capital Management
New Jersey
$15.9K – – –
Morgan Stanley
23
Morgan Stanley
New York
$12K +$12.3K +1,479 New
Citigroup
24
Citigroup
New York
$6K +$6.96K +835 New
PA
25
Perceptive Advisors
New York
– -$1.11M -159,309 Closed
1
2

ABUS Hedge Fund Activity: Q4 2013 in Review

24 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q4 2013, worth a combined $39.5M — up 341% from $8.95M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ABUS positions and 6 closed out — a net gain of 6 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Franklin Resources, opening a new position worth an estimated $16.8M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $1.11M sold.

  • 24 institutional investors held Arbutus Biopharma (ABUS) as of Q4 2013, up from 18 in Q3 2013.
  • Funds reported $39.5M of Arbutus Biopharma stock for Q4 2013, up 341% quarter-over-quarter.
  • 12 funds opened new Arbutus Biopharma positions in Q4 2013 and 6 closed out, a net change of +6 holders.
  • The largest Arbutus Biopharma buyer in Q4 2013 was Franklin Resources, an estimated $16.8M added.
  • The largest Arbutus Biopharma seller in Q4 2013 was Perceptive Advisors, an estimated $1.11M sold.

Based on aggregated 13F filings for Q4 2013.